Edwards SAPIEN XT Transcatheter Heart Valve ... These would include the use of: If both a cardiovascular surgeon and cardiologist determine that you are to high risk for standard aortic valve ...

NEW YORK, NY / ACCESSWIRE / December 3, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSE:EW) investment and want to ...

Class Action Lawsuit Against Edwards Lifesciences Corporation (EW): The litigation is focused on the propriety of Edwards Lifesciences' disclosures about its core product, the Transcatheter Aortic ...

Edwards Lifesciences (NYSE:EW) today announced one-year data highlighting strong performance from its Sapien 3 Ultra Resilia ...

Edwards Lifesciences Corporation (NYSE ... As the company strives to maintain its dominant position in the Transcatheter Aortic Valve Replacement (TAVR) market while expanding into new territories ...

Hospital heart team capacity constraints continued to limit Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) sales in the third quarter of 2024, company executives said ...

New York, New York-- (Newsfile Corp. - December 3, 2024) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE ...

US medical device giant Edwards Lifesciences has said patients are experiencing “outstanding one-year outcomes” and lower ...

Abbott has taken a step forward in the development of a new addition to its structural heart portfolio, completing the first ...